Oral Cancer – Pipeline Review, H1 2013Global Markets DirectFebruary 28, 2013 40 Pages - SKU: GMD4986573 |
- Introduction
- Global Markets Direct Report Coverage
- Oral Cancer Overview
- Therapeutics Development
- An Overview of Pipeline Products for Oral Cancer
- Oral Cancer Therapeutics under Development by Companies
- Oral Cancer Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Pre-Clinical Stage Products
- Comparative Analysis
- Oral Cancer Therapeutics – Products under Development by Companies
- Oral Cancer Therapeutics – Products under Investigation by Universities/Institutes
- Companies Involved in Oral Cancer Therapeutics Development
- NexMed, Inc.
- Oral Cancer – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- HPPH - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- bevacizumab + [cisplatin] + [docetaxel] + [fluorouracil] - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Survivin-Derived Peptide Vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Docetaxel + Cisplatin + 5-Fluorouracil - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Taxotere + Cisplatin + 5-FU - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- vesnarinone - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- curcumin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- paclitaxel - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- celecoxib - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- interleukin-15 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Oral Cancer Therapeutics – Drug Profile Updates
- Oral Cancer Therapeutics – Discontinued Products
- Oral Cancer Therapeutics - Dormant Products
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Oral Cancer, H1 2013
- Products under Development for Oral Cancer – Comparative Analysis, H1 2013
- Number of Products under Development by Companies, H1 2013
- Number of Products under Investigation by Universities/Institutes, H1 2013
- Comparative Analysis by Late Stage Development, H1 2013
- Comparative Analysis by Mid Clinical Stage Development, H1 2013
- Comparative Analysis by Early Clinical Stage Development, H1 2013
- Comparative Analysis by Pre-Clinical Stage Development, H1 2013
- Products under Development by Companies, H1 2013
- Products under Investigation by Universities/Institutes, H1 2013
- NexMed, Inc., H1 2013
- Assessment by Monotherapy Products, H1 2013
- Assessment by Combination Products, H1 2013
- Assessment by Stage and Route of Administration, H1 2013
- Assessment by Stage and Molecule Type, H1 2013
- Oral Cancer Therapeutics – Drug Profile Updates
- Oral Cancer Therapeutics – Discontinued Products
- Oral Cancer Therapeutics – Dormant Products
- List of Figures
- Number of Products under Development for Oral Cancer, H1 2013
- Products under Development for Oral Cancer – Comparative Analysis, H1 2013
- Products under Development by Companies, H1 2013
- Products under Investigation by Universities/Institutes, H1 2013
- Late Stage Products, H1 2013
- Mid Clinical Stage Products, H1 2013
- Early Clinical Stage Products, H1 2013
- Pre-Clinical Stage Products, H1 2013
- Assessment by Monotherapy Products, H1 2013
- Assessment by Combination Products, H1 2013
- Assessment by Route of Administration, H1 2013
- Assessment by Stage and Route of Administration, H1 2013
- Assessment by Molecule Type, H1 2013
- Assessment by Stage and Molecule Type, H1 2013
Research assistance
We can help you find what you need. Call us or write us: Need help in your search?
US: 800.298.5699
Int'l: +1.240.747.3093
Related Markets
- Diseases & Conditions
- Cancer Treatment
- Pharmaceuticals
- Drug Discovery
- Therapeutic Area
- Oncology/Hematology
Oncology/Hematology Reports
